Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

ClinicalTrials.gov ID: NCT01936363

Public ClinicalTrials.gov record NCT01936363. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 12:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a double blind, randomized, placebo-controlled, 2-arm, Phase 2 trial investigating the efficacy and safety of combination therapy of pimasertib plus SAR245409 and pimasertib placebo administered once per day compared to pimasertib administered twice per day plus SAR245409 placebo administered once per day in participants with previously treated unresectable low-grade serous ovarian or peritoneal carcinoma or serous borderline ovarian or peritoneal tumors.

Study identification

NCT ID: NCT01936363
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: EMD Serono; Industry
Enrollment: 65 participants

Conditions and interventions

Conditions

Ovarian Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 29, 2013
Primary completion: May 30, 2015
Completion: Nov 29, 2017
Last update posted: Dec 11, 2018

2013 – 2017

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 16

Facility	City	State	ZIP	Site status
Research site	Augusta	Georgia	30912	—
Research site	Chicago	Illinois	60637	—
Research site	Indianapolis	Indiana	46202	—
Research site	Silver Spring	Maryland	20910	—
Research site	Boston	Massachusetts	02114	—
Research site	Boston	Massachusetts	02215-5450	—
Research site	Ann Arbor	Michigan	48109	—
Research site	Detroit	Michigan	48202	—
Research site	Kansas City	Missouri	64111	—
Research site	St Louis	Missouri	63110	—
Research site	Kalispell	Montana	59901	—
Research site	New York	New York	10065	—
Research site	Cincinnati	Ohio	45219	—
Research site	Columbus	Ohio	43210	—
Research site	Middletown	Ohio	45042	—
Research site	Nashville	Tennessee	37203	—
Research site	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01936363, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 11, 2018 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01936363 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →